Rationale and design of a randomized controlled trial of the effect of retinol and vitamin D supplementation on treatment in active pulmonary tuberculosis patients with diabetes

BMC Infectious Diseases

Jing Cai⁵  Shanliang Zhao⁴  Yufeng Liu³  Xiuxia Han¹  Ib Christian Bygbjerg²  Aiguo Ma⁵  Qiuzhen Wang⁵ 

[1] Microbiology teaching and research division, Medical College of Qingdao University, 308 Ningxia Road, Qingdao 266021, China;Department of International Health, University of Copenhagen, Copenhagen DK-1014, Denmark;Clinical department, Qingdao Chest Hospital, 896 Chongqing Middle Road, Qingdao 266000, China;Clinical department, Lingyi Chest Hospital, East Fenghuang Avenue, Linyi 276000, China;The Institute of Human Nutrition, Medical College of Qingdao University, 38 Dengzhou Road, Qingdao 266021, China

关键词: Randomized controlled trial;    Cholecalciferol;    Retinol;    Diabetes mellitus;    Pulmonary tuberculosis;   

Others  :  1171019
DOI  :  10.1186/1471-2334-13-104

 received in 2013-01-09, accepted in 2013-02-18,  发布年份 2013

【 摘 要 】

Background

The association between pulmonary tuberculosis (PTB) and diabetes mellitus (DM) has been previously attracted much attention. Diabetes alters immunity to tuberculosis, leading to more frequent treatment failure in TB patients with DM. Moreover, TB and DM often coincide with micronutrients deficiencies, such as retinol and vitamin D, which are especially important to immunity of the body and may influence pancreas β-cell function. However, the effects of retinol and vitamin D supplementation in active TB patients with diabetes on treatment outcomes, immune and nutrition state are still uncertain. We are conducting a randomized controlled trial of vitamin A and/or D in active PTB patients with DM in a network of 4 TB treatment clinics to determine whether the supplementation could improve the outcome in the patients.

Methods/design

This is a 2×2 factorial trial. We plan to enroll 400 active PTB patients with DM, and randomize them to VA (2000 IU daily retinol); VD (400 IU daily cholecalciferol); VAD (2000 IU daily retinol plus 400 IU cholecalciferol) or control (placebo) group. Our primary outcome measure is the efficacy of anti-tuberculosis treatment and ameliorating of glucose metabolism, and the secondary outcome measure being immune and nutrition status of the subjects. Of the first 37 subjects enrolled: 8 have been randomized to VA, 10 to VD, 9 to VAD and 10 to control. To date, the sample is 97.3% Han Chinese and 91.9% female. The average fasting plasma glucose level is 12.19 mmol/L.

Discussion

This paper describes the design and rationale of a randomized clinical trial comparing VA and/or VD supplementation to active pulmonary TB patients with DM. Our trial will allow rigorous evaluation of the efficacy of the supplementation to active TB and DM therapy for improving clinical outcomes and immunological condition. This detailed description of trial methodology can serve as a template for the development of future treatment scheme for active TB patient with DM.

Trial registration

ChiCTR-TRC-12002546

【 授权许可】

   
2013 Wang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Dooley KE, Chaisson RE: Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009, 9:737-746.
• [2]Cheng MH: Asia-Pacific faces diabetes challenge. Lancet 2010, 375:2207-2210.
• [3]Güler M, Unsal E, Dursun B, Aydln O, Capan N: Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007, 61:231-235.
• [4]Restrepo BI, Fisher-Hoch SP, Smith B, Jeon S, Rahbar MH, McCormick JB, Nuevo Santander Tuberculosis Trackers: Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes. AmJTrop Med Hyg 2008, 79:541-544.
• [5]Rwangabwoba JM, Fischman H, Semba RD: Serum vitamin A levels during tuberculosis and human immunodeficiency virus infection. Int J Tuberc Lung Dis 1998, 2:771-773.
• [6]Jason J, Archibald LK, Nwanyanwu OC, Sowell AL, Buchanan I, Larned J, Bell M, Kazembe PN, Dobbie H, Jarvis WR: Vitamin A levels and immunity in humans. Clin Diagn Lab Immunol 2002, 9:616-621.
• [7]Pfeffer PE, Hawrylowicz CM: Vitamin D and lung disease. Thorax 2012, 67:1018-1020.
• [8]Sung CC, Liao MT, Lu KC, Wu CC: Role of vitamin D in insulin resistance. J Biomed Biotechnol 2012.
• [9]Khoo AL, Chai LY, Koenen HJ, Oosting M, Steinmeyer A, Zuegel U, Joosten I, Netea MG, van der Ven AJ: Vitamin D(3) down-regulates proinflammatory cytokine response to Mycobacterium tuberculosis through pattern recognition receptors while inducing protective cathelicidin production. Cytokine 2011, 55:294-300.
• [10]Yamshchikov AV, Kurbatova EV, Kumari M, Blumberg HM, Ziegler TR, Ray SM, Tangpricha V: Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis. Am J Clin Nutr 2010, 92:603-611.
• [11]Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ, Rainbow SJ, Berry JL, Griffiths CJ: A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007, 176:208-213.
• [12]Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M: Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009, 179:843-850.
• [13]Karnchanasorn R, Ou HY, Chiu KC: Plasma 25-hydroxyvitamin D levels are favorably associated with β-cell function. Pancreas 2012, 41:863-868.
• [14]Mitri J, Dawson-Hughes B, Hu FB, Pittas AG: Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr 2011, 94:486-494.
• [15]Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, Nelwan RH, Parwati I, van der Meer JW, van Crevel R: The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007, 45:428-435.
• [16]Mboussa J, Monabeka H, Kombo M, Yokolo D, Yoka-Mbio A, Yala F: Course of pulmonary tuberculosis in diabetics. Rev Pneumol Clin 2003, 59:39-44.
• [17]Wang CS, Yang CJ, Chen HC, Chuang SH, Chong IW, Hwang JJ, Huang MS: Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009, 137:203-210.
• [18]Zhao S, Li R, Li Y, Chen W, Zhang Y, Chen G: Roles of vitamin A status and retinoids in glucose and fatty acid metabolism. Biochem Cell Biol 2012, 90:142-152.
• [19]Greenstein RJ, Su L, Brown ST: Vitamins A & D inhibit the growth of mycobacteria in radiometric culture. PLoS One 2012, 7:e29631.
• [20]Visser ME, Grewal HM, Swart EC, Dhansay MA, Walzl G, Swanevelder S, Lombard C, Maartens G: The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr 2011, 93:93-100.
• [21]Shidfar F, Aghasi M, Vafa M, Heydari I, Hosseini S, Shidfar S: Effects of combination of zinc and vitamin A supplementation on serum fasting blood sugar, insulin, apoprotein B and apoprotein A-I in patients with type I diabetes. Int J Food Sci Nutr 2010, 61:182-191.
• [22]Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD: The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010, 53:2112-2119.
• [23]Eftekhari MH, Akbarzadeh M, Dabbaghmanesh MH, Hasanzadeh J: Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients. Asia Pac J Clin Nutr 2011, 20:521-526.
• [24]Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward NJ, Venton TR, Barnes KE, Mullett CJ, Coussens AK, Rutterford CM, Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V, Drobniewski FA, Eldridge SM, Griffiths CJ: High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011, 377:242-250.
• [25]Ministry of Health: Survey on the status of nutrition and health of the chinese people. Beijing, China: Ministry of Health; 2002.